Literature DB >> 18500169

HPV typing in women with cervical precancerous and cancerous lesions in northwestern Iran.

Mohsen Esmaeili1, Mortaza Bonyadi, Ali Dastranj, Masoumeh Alizadeh, Manizheh Sayyah Melli, Mehri Jafari Shobeiri.   

Abstract

BACKGROUND/AIMS: The role of human papillomavirus (HPV) in the etiology of cervical cancer is now well established. This investigation was designed to study the prevalence of the four most common high-risk HPVs in the archival tissues with precancerous and cancerous lesions from patients from northwestern Iran.
METHODS: 133 formalin-fixed paraffin-embedded tissue specimens were tested for HPV DNA by using GP5+/6+-based general PCR and two type-specific PCRs.
RESULTS: In total, 84 (64%) out of 131 amplifiable samples were positive for HPV DNA. The most prevalent oncogenic HPV was type 16 (67.6%) followed by types 31 (22.8%), 18 (7.6%) and 33 (1%). Multiple HPV infections were present in 20 (15.3%) of the 131 samples. Notably, of these 20 cases with multiple infections, 15 were from patients with invasive cervical cancer.
CONCLUSIONS: The multiplicity of HPV genotypes was noted in invasive cervical carcinoma samples, along with rather different circulating HPV types in the study population. Hence, relevant HPV typing information in cervical carcinoma is very important for planning more efficient screening programs and for further HPV vaccine design. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18500169     DOI: 10.1159/000134917

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  6 in total

Review 1.  Human papillomaviruses-related cancers. Presence and prevention strategies in the Middle east and north African regions.

Authors:  Ala-Eddin Al Moustafa; Rana Al-Awadhi; Nabiha Missaoui; Ishag Adam; Raika Durusoy; Lina Ghabreau; Nizar Akil; Hussain Gadelkarim Ahmed; Amber Yasmeen; Ghazi Alsbeih
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  The Association of High Risk Human Papillomaviruses in Patients With Cervical Cancer: An Evidence Based Study on Patients With Squamous Cell Dysplasia or Carcinoma for Evaluation of 23 Human Papilloma Virus Genotypes.

Authors:  Ahmad Piroozmand; Seyed Mostafa Mostafavi Zadeh; Azita Madani; Reza Soleimani; Reza Nedaeinia; Mohammad Niakan; Amir Avan; Mostafa Manian; Mohammad Moradi; Zahra Eftekhar
Journal:  Jundishapur J Microbiol       Date:  2016-02-17       Impact factor: 0.747

3.  Frequency of Human Papillumavirus among Women with High-Grade Squamous Intraepithelial Lesions and Invasive Cervical Cancer Attending Shahid Beheshti University of Medical Sciences Clinics, Tehran, Iran.

Authors:  Nahid Khodakarami; Afshin Moradi; Hamidreza Mirzaei; Farah Farzaneh; Parvin Yavari; Mohamad Esmaeil Akbari
Journal:  Iran J Public Health       Date:  2014-11       Impact factor: 1.429

4.  Prevalence of human papilloma virus (HPV) genotypes between outpatients males and females referred to seven laboratories in Tehran, Iran.

Authors:  Iman Rezaee Azhar; Mahmood Yaghoobi; Mir Majid Mossalaeie; Abolghasem Kollaee Darabi; Amir Houshang Nejadeh; Mahbobeh Jamshidi; Ali Ahani; Masoud Karkhane Mahmoodi; Leila Ghalichi; Ayda Shabanzadeh; Angila Ataei-Pirkooh; Arezoo Marjani; Azam Khamseh; Motahareh Shafiei; Parastoo Hosseini; Saber Soltani; Milad Zandi; Parsa Ghafari; Amir Aboofazeli; Azam Ghaziasadi; Seyed Mohammad Jazayeri
Journal:  Infect Agent Cancer       Date:  2022-03-05       Impact factor: 2.965

5.  Prevalence of HPV Infection and High Risk HPV Genotypes (16, 18), among Monogamous and Polygamous Women, In Zabol, Iran.

Authors:  I Shahramian; Z Heidari; Hr Mahmoudzadeh-Sagheb; A Moradi; F Forghani
Journal:  Iran J Public Health       Date:  2011-09-30       Impact factor: 1.429

6.  Prevalence and genotyping of high risk human papillomavirus in cervical cancer samples from Punjab, Pakistan.

Authors:  Abida Siddiqa; Maidah Zainab; Ishtiaq Qadri; Muhammad Faraz Bhatti; Joanna L Parish
Journal:  Viruses       Date:  2014-07-17       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.